Biotech News

MAIA Biotechnology Reports Strong Enrollment and Dosing Momentum in Pivotal Phase 3 Non-Small Cell Lung Cancer Trial

Maia Biotechnology (MKT)Maia Biotechnology2026-06-25 13:46 ESTClinical readout

MKT (MKT) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is mkt.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Open original release

Related news

MKTMaia Biotechnology2026-06-25 13:46 EST

MAIA Biotechnology Completes International Enrollment in Part C of Phase 2 THIO-101 Expansion Trial in Third-Line Non-Small Cell Lung Cancer

MKTMaia Biotechnology2026-06-25 13:46 EST

MAIA Biotechnology Opens Enrollment for Phase 2 Expansion Trial of Novel Telomere-Targeting Agent at Winship Cancer Institute of Emory University

MKTMaia Biotechnology2026-06-25 13:46 EST

MAIA Biotechnology Activates and Opens Enrollment at Second U.S. Clinical Site for International Phase 2 THIO-101 Expansion Trial

MKTMaia Biotechnology2026-06-25 13:46 EST

MAIA Biotechnology Receives FDA Clearance to Open U.S. Enrollment in Ongoing Phase 2 THIO-101 Trial Expansion

MKTMaia Biotechnology2026-06-25 13:46 EST

MAIA Biotechnology Announces Open Market Purchases by CEO and Director

MKTMaia Biotechnology2026-06-25 13:46 EST

MAIA Biotechnology Presents Trial in Progress Poster for Pivotal Phase 3 Clinical Trial of Novel Telomere Targeting Agent at 2026 Annual Meeting of American Society of Clinical Oncology

MKTMaia Biotechnology2026-06-25 13:46 EST

MAIA Biotechnology Announces $1.51 Million Private Placement

MKTMaia Biotechnology2026-06-25 13:46 EST

MAIA Biotechnology Board Members Continue to Participate in Private Placement Financings

MKTMaia Biotechnology2026-06-25 13:46 EST

MAIA Biotechnology Advances Ateganosine Cancer Treatment Program, Outlines Targeted 2026 Clinical Milestones and Growth Momentum

MKTMaia Biotechnology2026-06-25 13:46 EST

MAIA Biotechnology’s Phase 3 Momentum Demonstrates Potential Breakthrough Anticancer Opportunity in $50 Billion Immunotherapy Market

View all latest news

Maia Biotechnology

Maia Biotechnology is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.

Recent company news

MKTMaia Biotechnology2026-06-26 02:27 EST

MAIA Biotechnology Completes International Enrollment in Part C of Phase 2 THIO-101 Expansion Trial in Third-Line Non-Small Cell Lung Cancer

MKTMaia Biotechnology2026-06-26 02:27 EST

MAIA Biotechnology Opens Enrollment for Phase 2 Expansion Trial of Novel Telomere-Targeting Agent at Winship Cancer Institute of Emory University

MKTMaia Biotechnology2026-06-26 02:27 EST

MAIA Biotechnology Activates and Opens Enrollment at Second U.S. Clinical Site for International Phase 2 THIO-101 Expansion Trial

MKTMaia Biotechnology2026-06-26 02:27 EST

MAIA Biotechnology Reports Strong Enrollment and Dosing Momentum in Pivotal Phase 3 Non-Small Cell Lung Cancer Trial

MKTMaia Biotechnology2026-06-26 02:27 EST

MAIA Biotechnology Receives FDA Clearance to Open U.S. Enrollment in Ongoing Phase 2 THIO-101 Trial Expansion

Stock data

Close: —
Market cap: —
Exchange: NYSE
Sector: Biotechnology
Location: United States